Icatibant Drug Discount Agreement
Titre original de l'avis
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Icatibant (ATC-Code nach WHO: B06AC02)
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
30 / 100
Facteurs de risque
No guaranteed minimum purchase quantities; actual demand depends on prescribing behavior and patient numbers.
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded, which t...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Aperçu
Moderate opportunityFaits clés
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Conclusion of non-exclusive discount agreements for Icatibant (ATC B06AC02)
- Supply of pharmaceutical products to the AOK PLUS health insurance for patients in Saxony and Thuringia
Afficher le résumé complet
Non-exclusive drug discount agreement for Icatibant under the Open-House model. Any interested pharmaceutical company can participate. No guaranteed volumes, no exclusive rights. The contract ends at the latest on 31 May 2028. The procedure is published for transparency but is not a public procurement subject to EU directives.
Risques
No guaranteed minimum purchase quantities; actual demand depends on prescribing behavior and patient numbers.
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded, which t...
L'analyse peut être incomplète
Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.
Exigences clés
Technical
- Participant must be a pharmaceutical undertaking as defined in § 4 Abs. 18 AMG
Eligibility
- Must submit declaration of no exclusion grounds per §§ 123, 124 GWB
Administrative
- Must submit declaration regarding Russia sanctions (EU Regulation 833/2014)
Les exigences peuvent être incomplètes.
Critères d'attribution
Lot 1
Acheteur
Localisation
Erfurt, DEU
Site web
Profil acheteur
Identifiant
DE256878834
Activité
Health
Lots (1)
LOT-0001
Icatibant Drug Discount Agreement
Non-exclusive discount agreement for pharmaceuticals containing Icatibant (ATC B06AC02). Open to all qualified pharmaceutical undertakings. No minimum purchase quantities. Contract ends 31 May 2028. The agreement may be terminated earlier if exclusive agreements are concluded.
Localisation
Durée
Catégorie
Critères d'attribution
Date limite
Détails des critères
No award criteria
participation is open to all who meet the requirements and accept the terms.
Note sur la valeur
Afficher les données TED originales
Titre original du lot
Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Icatibant (ATC-Code nach WHO: B06AC02)
Description TED originale
Siehe Kurzbeschreibung
Détails de la procédure
- Date de publication
- 12 Mar 2026
- Langues
- German
Métadonnées de référence
- Base juridique
- 32014L0024
Identifiants de référence
- ID de l'appel d'offres
- 174735-2026
Documents (1)
Appels d'offres similaires
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Score d'opportunité
Pourquoi ce score ?
Opportunité
50 / 100
Complexité
30 / 100
Facteurs de risque
No guaranteed minimum purchase quantities; actual demand depends on prescribing behavior and patient numbers.
The buyer reserves the right to terminate the open-house procedure early if exclusive agreements are concluded, which t...
Analyse approfondie du portefeuille
Utilise:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications